Ramkrishna Mitra

10PUBLICATIONS
73CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 11, 2025
Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC.

Pablo Llerena, Hani Samarah, Kathryn Nunes

|Dec 08, 2023
4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress.

Marissa L Calbert, Gurushankar Chandramouly, Clare M Adams

|Jun 28, 2023
Decoding the lncRNAome Across Diverse Cellular Stresses Reveals Core p53-effector Pan-cancer Suppressive lncRNAs.

Ramkrishna Mitra, Clare M Adams, Christine M Eischen

|Mar 13, 2023
Genomic Landscape and Potential Regulation of RNA Editing in Drug Resistance.

Xu Zhou, Ramkrishna Mitra, Fei Hou

|Feb 03, 2023
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.

Clare M Adams, Ramkrishna Mitra, Youcai Xiao

Pageof 2